WED 061 ‘real life’ experience with brivaracetam as add-on treatment for epilepsy

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Brivaracetam received its UK licence as an adjuvant drug for focal epilepsy in adults in 2016. There is little data on its efficacy and tolerability in ‘real life’ settings. We present an interim analysis of a multicentre service evaluation of brivaracetam.

Methods

Data was retrospectively collected from clinical records at two UK centres of consecutive patients treated with brivaracetam and at least one follow up. Data were also extracted on previous levetiracetam use. Seizure frequency was categorised at baseline and follow-up (daily/weekly/monthly/yearly/none).Results: Of the 44 patients identified (17 male, mean age 39, range 19–66), 75% had a history of levetiracetam exposure (LE+) and 25% did not (LE−). Mean brivaracetam exposure was 10.3 months (2–21), the mean daily dose was 200 mg (50–400). Retention was 91% vs 100% in LE+ versus LE− groups at 3 months and 82% in both groups at 6 months. Seizure category improvements were seen in 20%/36.4% in the LE+ vs LE− groups, seizure category deteriorations in 0% vs 9%. There were no serious adverse events.

Conclusion

Brivaracetam emerges as a potentially useful adjuvant medication for focal epilepsy. It may be better tolerated by some patients than Levetiracetam and more effective than this drug.

Related Topics

    loading  Loading Related Articles